Gilead Sciences AI Stock Analysis
Want to see GILD full AI Analyst Report?
Gilead Sciences (GILD) AI Stock Analysis
Gilead Sciences
(NASDAQ:GILD)
The score is supported most by strong and resilient cash generation and a very constructive earnings call with raised guidance and broad product momentum. Technicals also show a clear uptrend, though momentum indicators are stretched. Offsetting these positives are weak/volatile reported profitability (TTM losses) and an unattractive/less-informative valuation signal from the negative P/E, alongside noted medium-term headwinds (notably the 2028 Biktarvy pricing impact).
Gilead Sciences Key Performance Indicators (KPIs)
Revenue by TypeAnalyzes income from different sources, highlighting which areas are driving growth and which might be underperforming, crucial for assessing the company's financial health and strategic focus.
Product sales are the clear growth engine — steady, upward momentum driven by HIV/PrEP strength and oncology launches that prompted management to raise product/base guidance. ‘Other’ is highly erratic and driven by one‑off items (nonrecurring other revenue, licensing/transactional effects), producing outsized spikes that can misleadingly swing reported results. For investors, prioritize the underlying product trajectory and HIV/PrEP/Trodelvy momentum rather than headline EPS volatility from acquisition accounting and tax distortions; watch cell‑therapy softness and lower COVID sales as potential near‑term offsets to product gains.
Gilead Sciences (GILD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $207.86B
- Dividend Yield
- 1.94%
- Average Volume (3M)
- 5.95M
- Price to Earnings (P/E)
- -54.1
- Beta (1Y)
- 0.26
- Revenue Growth
- 6.92%
- EPS Growth
- -147.65%
- Country
- US
- Employees
- 17,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Gilead Sciences Business Overview & Revenue Model
Company Description
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to a...
How the Company Makes Money
Gilead makes money primarily by selling branded prescription medicines to wholesalers, distributors, pharmacies, hospitals, government purchasers, and other healthcare providers across the U.S. and international markets. Its largest revenue streams a...
Gilead Sciences Earnings Call Summary
The call was strongly positive overall. Gilead reported its strongest base business growth in more than a decade, broad-based product momentum, improved margins, raised revenue and adjusted EPS guidance, significant pipeline progress, and continued diversification across HIV, oncology, inflammation, and cell therapy. These positives outweighed the stated challenges, including the projected $1.5 billion 2028 Biktarvy revenue impact from CMS pricing, cell therapy declines, clinical holds, lower Veklury and HCV sales, and acquisition-related charges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Gilead now expects 2026 base business sales to range between $30.7 billion and $31 billion, total product sales to range between $31 billion and $31.3 billion, HIV sales to grow approximately 12% year-over-year, Yeztugo sales of approximately $1 billion for the full year, cell therapy sales to decline mid-teens percentage year-over-year, Veklury sales of approximately $300 million, acquired IPR&D of approximately $12.9 billion, R&D expenses to increase a mid- to high single-digit percentage on a dollar basis and SG&A expenses to increase by a high single-digit percentage on a dollar basis, an effective tax rate between 220% and 165%, non-GAAP loss per share between $1.20 and $0.85, and, excluding approximately $9.95 per share, non-GAAP diluted EPS of $8.75 to $9.10, raised $0.25 on both ends from illustrative August guidance; for 2028, Gilead expects a total net impact to Biktarvy revenue of approximately $1.5 billion, total HIV revenue to grow compared to 2027, and both total product sales and earnings per share to grow compared to 2027.
Gilead Sciences Financial Statement Overview
Summary
Cash flow is a major strength (Cash Flow Score 84) with very strong operating cash flow and free cash flow even during the TTM net loss, supporting resilience and shareholder returns. This is partially offset by weak and volatile reported profitability (Income Statement Score 42) with a sharp TTM deterioration to operating losses and a sizable net loss. The balance sheet is serviceable (Balance Sheet Score 56) with manageable leverage, but returns on equity turned negative in TTM due to the loss.
Income Statement
42NeutralBalance Sheet
56NeutralCash Flow
84Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.99B | 29.44B | 28.75B | 27.12B | 27.28B | 27.30B |
| Gross Profit | 24.77B | 23.21B | 22.50B | 20.62B | 21.62B | 20.70B |
| EBITDA | 1.29B | 13.58B | 4.43B | 10.50B | 8.85B | 11.33B |
| Net Income | -3.86B | 8.51B | 480.00M | 5.67B | 4.59B | 6.22B |
Balance Sheet | ||||||
| Total Assets | 51.41B | 59.02B | 58.99B | 62.13B | 63.17B | 67.95B |
| Cash, Cash Equivalents and Short-Term Investments | 6.44B | 9.61B | 11.57B | 7.26B | 6.38B | 6.52B |
| Total Debt | 26.23B | 24.94B | 26.71B | 24.99B | 25.23B | 26.70B |
| Total Liabilities | 38.45B | 36.41B | 39.75B | 39.38B | 41.96B | 46.89B |
| Stockholders Equity | 13.04B | 22.70B | 19.33B | 22.83B | 21.24B | 21.07B |
Cash Flow | ||||||
| Free Cash Flow | 13.78B | 9.46B | 10.30B | 7.42B | 8.34B | 10.80B |
| Operating Cash Flow | 14.48B | 10.02B | 10.83B | 8.01B | 9.07B | 11.38B |
| Investing Cash Flow | -10.65B | -4.79B | -3.45B | -2.27B | -2.47B | -3.13B |
| Financing Cash Flow | -4.69B | -7.75B | -3.43B | -5.13B | -6.47B | -8.88B |
Gilead Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GILD, the sentiment is Positive. The current price of 167.58 is above the 20-day moving average (MA) of 164.84, above the 50-day MA of 155.35, and above the 200-day MA of 140.72, indicating a bullish trend. The MACD of 4.30 indicates Positive momentum. The RSI at 58.37 is Neutral, neither overbought nor oversold. The STOCH value of 30.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GILD.
Gilead Sciences Risk Analysis
Gilead Sciences disclosed 22 risk factors in its most recent earnings report. Gilead Sciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksGilead Sciences Peers Comparison
Overall Rating
NVS72Outperform
JNJ70Outperform
BMY66Neutral
PFE66Neutral
GILD66Neutral
MRK64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $295.59B | 31.08 | 24.24% | 2.96% | 1.64% | -28.72% | |
| 70Outperform | $680.19B | 43.01 | 19.55% | 1.87% | 7.81% | -35.95% | |
| 66Neutral | $128.63B | 13.94 | 43.88% | 4.00% | 4.19% | 52.55% | |
| 66Neutral | $164.50B | 40.86 | 4.60% | 5.96% | 1.34% | -58.96% | |
| 66Neutral | $207.86B | -54.06 | -21.74% | 1.94% | 6.92% | -147.65% | |
| 64Neutral | $356.13B | 147.39 | 5.29% | 2.35% | 5.21% | -86.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GILD | Gilead Sciences | 167.58 | 43.47 | 35.02% | |
| BMY | Bristol-Myers Squibb Company | 62.93 | 17.88 | 39.67% | |
| JNJ | Johnson & Johnson | 282.55 | 86.96 | 44.46% | |
| MRK | Merck & Company | 144.46 | 50.78 | 54.21% | |
| NVS | Novartis AG | 160.20 | 34.65 | 27.60% | |
| PFE | Pfizer Inc | 28.86 | 5.01 | 21.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
